At EHA, Benoit Tessoulin, MD, PhD, shared data showing the epcoritamab/R² combination benefitted all relapsed/refractory follicular lymphoma subgroups.
Benoit Tessoulin, MD, PhD
Advertisement
Articles by Benoit Tessoulin, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Regulatory T-Cell Immunotherapy in Hematologic Malignancies
2
What Does The Future Hold for Thoracic Oncology and AI Use in Cancer?
3
Illuminating Optimal CAR T-Cell Therapies Across Large B-Cell Lymphoma Groups
4
Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis
5